SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy
Table 1
Patient characteristics (total number of patients = 20).
Variable
N (%)
Site
Dana-Farber Cancer Institute
3 (15)
Massachusetts General Hospital
3 (15)
Memorial Sloan Kettering Cancer Center
5 (25)
Ohio State University
6 (30)
University of Michigan
3 (15)
Sex
Female
14 (70)
Male
6 (30)
Ethnicity
Hispanic or Latino
1 (5)
Not Hispanic or Latino
19 (95)
Race
Asian
2 (10)
Black or African heritage
3 (15)
White
15 (75)
Tumor location at diagnosis
Kidney
2 (10)
Liver
1 (5)
Others
6 (30)
Pelvis
1 (5)
Peritoneum
2 (10)
Uterus
8 (40)
Metastasis present at diagnosis
No
16 (80)
Yes
4 (20)
Site of metastasis
Abdomen
1 (5)
Colon
2 (10)
Kidney
1 (5)
Liver
4 (20)
Lung
12 (60)
Pancreas
1 (5)
Pelvis
2 (10)
Peritoneum
1 (5)
Spine
3 (15)
Thyroid
1 (5)
Others
3 (15)
More than one site of metastasis
6 (30)
Received prior radiation therapy
No
14 (70)
Yes
6 (30)
Received prior surgery
No
3 (15)
Yes
17 (85)
Prior regimens
Gemcitabine/docetaxel
20 (100)
Gemcitabine/vinorelbine
1 (5)
AIM (doxorubicin, ifosfamide, and mesna)
3 (15)
Dacarbazine
5 (25)
Doxorubicin
9 (45)
Ifosfamide
1 (5)
Pazopanib
7 (35)
Trabectedin
1 (5)
Others
10 (50)
Number of prior lines of therapy before study entry
